Latest news with #CettireLimited
Yahoo
2 days ago
- Business
- Yahoo
BrainChip Holdings And 2 Other ASX Penny Stocks To Watch
The Australian market is showing resilience, with ASX 200 futures indicating a slight gain despite global uncertainties such as Middle East tensions and U.S.-China trade discussions impacting Wall Street. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing opportunities for investors seeking growth at lower price points. These stocks can still present significant potential when supported by strong balance sheets and solid fundamentals, making them worth watching in the current market landscape. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.82 A$85.86M ★★★★★★ GTN (ASX:GTN) A$0.64 A$122.15M ★★★★★★ IVE Group (ASX:IGL) A$2.66 A$410.12M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.63 A$430.99M ★★★★★★ Tasmea (ASX:TEA) A$2.95 A$695.08M ★★★★★☆ Regal Partners (ASX:RPL) A$2.30 A$773.18M ★★★★★★ Accent Group (ASX:AX1) A$1.80 A$1.08B ★★★★☆☆ Lindsay Australia (ASX:LAU) A$0.73 A$231.53M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.33 A$158.01M ★★★★★★ CTI Logistics (ASX:CLX) A$1.80 A$144.98M ★★★★☆☆ Click here to see the full list of 1,006 stocks from our ASX Penny Stocks screener. Let's dive into some prime choices out of the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: BrainChip Holdings Ltd develops software and hardware solutions for artificial intelligence and machine learning across multiple regions, with a market cap of A$455.79 million. Operations: The company generates revenue from the technological development of designs, amounting to $0.40 million. Market Cap: A$455.79M BrainChip Holdings Ltd, with a market cap of A$455.79 million, is pre-revenue and currently unprofitable, generating only US$0.40 million in revenue. Despite this, the company has no debt and a stable cash runway exceeding one year based on current free cash flow. Recent collaborations include an agreement with Chelpis Quantum Corp for post-quantum cryptographic security chips and a partnership with ARQUIMEA for AI-powered water safety solutions. However, significant insider selling over the past three months raises caution. The management team's average tenure is 1.5 years, indicating relatively new leadership. Dive into the specifics of BrainChip Holdings here with our thorough balance sheet health report. Assess BrainChip Holdings' future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Cettire Limited operates as an online luxury goods retailer in Australia, the United States, and internationally with a market cap of A$177.28 million. Operations: The company generates its revenue primarily through online retail sales, amounting to A$781.98 million. Market Cap: A$177.28M Cettire Limited, with a market cap of A$177.28 million, is trading significantly below its estimated fair value and operates debt-free, alleviating concerns about interest payments. The company has seen its weekly volatility decrease over the past year and maintains strong short-term liquidity with assets exceeding liabilities. However, Cettire's recent earnings growth has been negative at -88.4%, compounded by a decline in profit margins from 3.6% to 0.3%. Recent board changes include Steven Fisher as Chair and Daniel Agostinelli joining as an Independent Non-Executive Director, both bringing extensive retail experience to guide future strategies. Click here to discover the nuances of Cettire with our detailed analytical financial health report. Evaluate Cettire's prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Core Lithium Ltd focuses on the development of lithium and various metal deposits in Northern Territory and South Australia, with a market cap of A$195.01 million. Operations: The company's revenue is primarily derived from the Finniss Lithium Project, which generated A$52.28 million. Market Cap: A$195.01M Core Lithium Ltd, with a market cap of A$195.01 million, is trading significantly below its estimated fair value and remains debt-free, which can be advantageous for financial flexibility. The company is currently unprofitable and faces less than a year of cash runway based on current free cash flow trends. Its short-term assets exceed both short- and long-term liabilities, indicating solid liquidity management. Recent updates on the Finniss Restart Study highlight efforts to optimize operations at its key lithium project to enhance productivity and reduce costs. However, profitability is not anticipated in the near term according to forecasts. Jump into the full analysis health report here for a deeper understanding of Core Lithium. Gain insights into Core Lithium's outlook and expected performance with our report on the company's earnings estimates. Jump into our full catalog of 1,006 ASX Penny Stocks here. Searching for a Fresh Perspective? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:BRN ASX:CTT and ASX:CXO. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
14-05-2025
- Business
- Yahoo
3 ASX Penny Stocks With Market Caps Over A$200M To Watch
The ASX200 is set to open slightly higher, reflecting a positive sentiment following the easing of trade tensions between China and the United States. For investors interested in exploring less conventional avenues, penny stocks offer intriguing possibilities despite their somewhat outdated label. These smaller or newer companies can present opportunities for significant returns when backed by solid financial foundations, and this article will highlight three such stocks that may offer potential value. Name Share Price Market Cap Financial Health Rating CTI Logistics (ASX:CLX) A$1.78 A$143.37M ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$1.46 A$68.87M ★★★★★★ IVE Group (ASX:IGL) A$2.67 A$411.67M ★★★★★☆ GTN (ASX:GTN) A$0.62 A$118.5M ★★★★★★ West African Resources (ASX:WAF) A$2.27 A$2.59B ★★★★★★ GR Engineering Services (ASX:GNG) A$2.79 A$466.92M ★★★★★★ Bisalloy Steel Group (ASX:BIS) A$3.35 A$158.96M ★★★★★★ Regal Partners (ASX:RPL) A$2.43 A$816.88M ★★★★★★ Navigator Global Investments (ASX:NGI) A$1.67 A$818.43M ★★★★★☆ NRW Holdings (ASX:NWH) A$2.90 A$1.33B ★★★★★☆ Click here to see the full list of 994 stocks from our ASX Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Boss Energy Limited explores for and produces uranium deposits in Australia and the United States, with a market capitalization of A$1.63 billion. Operations: Currently, there are no reported revenue segments for the company. Market Cap: A$1.63B Boss Energy Limited, with a market cap of A$1.63 billion, operates in the uranium sector and is currently pre-revenue. Despite being unprofitable, it has managed to reduce losses by 39.5% annually over the past five years and maintains a strong balance sheet with short-term assets of A$222.7 million exceeding both short-term and long-term liabilities. The company is debt-free, trading at 61.8% below its estimated fair value, but faces challenges such as an inexperienced management team averaging 1.2 years in tenure and recent financial results showing a net loss of A$9.5 million for H2 2024 despite sales of A$47.79 million. Navigate through the intricacies of Boss Energy with our comprehensive balance sheet health report here. Understand Boss Energy's earnings outlook by examining our growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Cettire Limited operates as an online luxury goods retailer in Australia, the United States, and internationally, with a market cap of A$211.59 million. Operations: The company generates revenue primarily through online retail sales, amounting to A$781.98 million. Market Cap: A$211.59M Cettire Limited, with a market cap of A$211.59 million, has seen its weekly volatility decrease from 19% to 12% over the past year, indicating reduced returns volatility. Despite no debt and short-term assets covering liabilities, Cettire's profit margins dropped to 0.3% from 3.6% last year due to large one-off gains impacting results. The board's recent changes include appointing Steven Fisher as Chair and Daniel Agostinelli as an Independent Director, both bringing extensive retail experience which may support strategic growth efforts amidst challenges like negative earnings growth of -88.4%. The stock trades at a significant discount below estimated fair value. Dive into the specifics of Cettire here with our thorough balance sheet health report. Examine Cettire's earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally with a market cap of A$1.15 billion. Operations: PolyNovo generates revenue of A$115.58 million from the development, manufacturing, and commercialization of its NovoSorb technology. Market Cap: A$1.15B PolyNovo Limited, with a market cap of A$1.15 billion, has demonstrated significant growth, reporting a 31.1% increase in revenue to A$91.6 million for the year-to-date ending March 2025. The company's earnings have accelerated considerably, growing by 270.2% over the past year and surpassing its five-year average growth rate of 46.5%. Despite an inexperienced management team with an average tenure of 1.3 years, PolyNovo's financial health remains robust with more cash than total debt and short-term assets exceeding liabilities. However, negative operating cash flow indicates potential challenges in covering debt obligations fully through cash generation alone. Unlock comprehensive insights into our analysis of PolyNovo stock in this financial health report. Review our growth performance report to gain insights into PolyNovo's future. Reveal the 994 hidden gems among our ASX Penny Stocks screener with a single click here. Contemplating Other Strategies? AI is about to change healthcare. These 23 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:BOE ASX:CTT and ASX:PNV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
28-01-2025
- Business
- Yahoo
Aston Minerals Leads These 3 ASX Penny Stocks
The Australian share market is poised for a modest gain today, driven by dovish sentiments around upcoming CPI numbers and a positive rebound in U.S. markets. In this context, penny stocks—often seen as smaller or newer companies—continue to offer intriguing opportunities for investors seeking affordability and growth potential. Despite the term's outdated feel, these stocks can still represent significant value when backed by strong financial health, as we'll see with three standout examples on the ASX. Name Share Price Market Cap Financial Health Rating Embark Early Education (ASX:EVO) A$0.78 A$143.12M ★★★★☆☆ LaserBond (ASX:LBL) A$0.58 A$67.99M ★★★★★★ SHAPE Australia (ASX:SHA) A$2.98 A$247.08M ★★★★★★ Austin Engineering (ASX:ANG) A$0.50 A$310.07M ★★★★★☆ Helloworld Travel (ASX:HLO) A$1.98 A$322.38M ★★★★★★ MaxiPARTS (ASX:MXI) A$1.89 A$104.55M ★★★★★★ GTN (ASX:GTN) A$0.53 A$104.08M ★★★★★★ IVE Group (ASX:IGL) A$2.14 A$331.46M ★★★★☆☆ Servcorp (ASX:SRV) A$4.98 A$491.43M ★★★★☆☆ SKS Technologies Group (ASX:SKS) A$1.59 A$235.35M ★★★★★★ Click here to see the full list of 1,031 stocks from our ASX Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Aston Minerals Limited is involved in the acquisition, exploration, and evaluation of mineral properties across Canada, Australia, Indonesia, and Europe with a market capitalization of A$15.54 million. Operations: The company's revenue is derived from its mineral exploration activities, amounting to A$0.16 million. Market Cap: A$15.54M Aston Minerals Limited, with a market capitalization of A$15.54 million, is pre-revenue and focuses on mineral exploration across multiple regions. The company maintains a strong financial position with no debt and short-term assets of A$5.3 million exceeding its short-term liabilities of A$196.8K. However, it faces challenges such as high share price volatility and an unprofitable status with increasing losses over the past five years at 20.1% annually. Recent leadership changes include Russell Bradford assuming the role of Chairman while retaining his Managing Director position, following Peter Breese's departure at the end of 2024. Dive into the specifics of Aston Minerals here with our thorough balance sheet health report. Assess Aston Minerals' previous results with our detailed historical performance reports. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Cettire Limited operates as an online luxury goods retailer in Australia, the United States, and internationally, with a market cap of A$510.86 million. Operations: The company generates revenue through online retail sales amounting to A$742.26 million. Market Cap: A$510.86M Cettire Limited, with a market cap of A$510.86 million, operates debt-free and maintains strong liquidity as its short-term assets (A$108.9M) surpass both short-term (A$100.7M) and long-term liabilities (A$3.5M). Despite high-quality earnings and a robust return on equity at 29%, the company has faced negative earnings growth of -34.4% over the past year, impacting profit margins which fell to 1.4% from last year's 3.8%. While trading significantly below estimated fair value, Cettire's reduced volatility may appeal to investors seeking stability in the penny stock space amidst forecasted earnings growth of 31.99% annually. Click here to discover the nuances of Cettire with our detailed analytical financial health report. Gain insights into Cettire's future direction by reviewing our growth report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Resonance Health Limited is a healthcare technology and services company that designs, develops, manufactures, and commercializes software-as-medical devices across various regions including Australia, the Asia Pacific, North America, Europe, the Middle East, and Africa with a market cap of A$27.12 million. Operations: The company's revenue is derived from three segments: CRO generating A$3.84 million, Services contributing A$4.54 million, and Trialswest adding A$0.20 million. Market Cap: A$27.12M Resonance Health Limited, with a market cap of A$27.12 million, recently achieved profitability, though its return on equity remains low at 1.5%. The company's financial health is supported by short-term assets (A$9.3M) exceeding both short-term (A$6.1M) and long-term liabilities (A$3.2M), alongside more cash than total debt and well-covered debt by operating cash flow. Despite increased volatility from 14% to 22%, Resonance Health trades significantly below estimated fair value, potentially offering an opportunity for investors mindful of its volatile share price and less experienced management team with an average tenure of 1.4 years. Get an in-depth perspective on Resonance Health's performance by reading our balance sheet health report here. Understand Resonance Health's track record by examining our performance history report. Navigate through the entire inventory of 1,031 ASX Penny Stocks here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:ASO ASX:CTT and ASX:RHT. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
